Proven, powerful results through the clinical study of ARCALYST

End the ongoing cycle of recurrent pericarditis with the only FDA-approved therapy proven to provide rapid relief and prevent future episodes.

scroll-down-arrow

Proven, powerful results through the clinical study of ARCALYST

End the ongoing cycle of recurrent pericarditis with the only FDA-approved therapy proven to provide rapid relief and prevent future episodes.

scroll-down-arrow
A TARGETED TREATMENT

How does ARCALYST work?

Targeted treatment with info

ARCALYST specifically targets IL-1 to address an underlying cause of autoinflammation in recurrent pericarditis.

It’s the only FDA-approved therapy indicated to treat recurrent pericarditis and reduce the risk of future flares.

 

ARCALYST was studied in 61 people who were diagnosed with recurrent pericarditis and experiencing at least a third flare. Some people were given ARCALYST and others were given a placebo. The results were then compared in order to understand how effective ARCALYST was at reducing the risk of future flares and providing symptom relief.

LASTING PREVENTION

ARCALYST significantly reduced the risk of future flares. 

96%
reduction in the risk of
recurrent pericarditis

In the ARCALYST study:

  • 2 of 30 patients (7%) who took ARCALYST had a recurrence
  • 23 of 31 patients (74%) who took placebo had a recurrence
     
RAPID RELIEF

People experienced a rapid treatment response with ARCALYST.

97 %
of patients experienced symptom relief as early as after the first dose

On average, treatment response was about 5 days.

During the study, people were asked to rate their pain based on a rating scale called the Numerical Rating Scale (NRS).

  • Most people experienced pain reduction within 5 days

Clinicians also assessed the levels of 
C-reactive protein (CRP). This is a protein that is detected in the body when inflammation is present.

  • Most patients experienced reduced levels of inflammation within 7 days
FREEDOM FROM PAIN AND STEROIDS

People experienced more pain-free days and were able to stop taking steroids with ARCALYST. 

People reported
92%
of days with minimal or no pericarditis pain compared to 40% of days for patients on placebo

In the study of ARCALYST:

  • ARCALYST significantly reduced the pain associated with recurrent pericarditis
  • All patients were able to successfully transition from steroids to ARCALYST only